KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Weighted Average) (2016 - 2025)

Jazz Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $61.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $61.0 million for Q4 2025, down 1.39% from a year ago — trailing twelve months through Dec 2025 was $61.0 million (down 1.39% YoY), and the annual figure for FY2025 was $61.0 million, down 1.39%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $61.0 million at Jazz Pharmaceuticals, roughly flat from $60.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for JAZZ hit a ceiling of $64.0 million in Q2 2023 and a floor of $56.5 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $61.9 million (2022), compared with a mean of $61.6 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 10.15% in 2021 and later fell 3.33% in 2024.
  • Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $59.7 million in 2021, then grew by 4.77% to $62.5 million in 2022, then increased by 1.2% to $63.3 million in 2023, then dropped by 2.3% to $61.8 million in 2024, then fell by 1.39% to $61.0 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $61.0 million (Q4 2025), $60.7 million (Q3 2025), and $61.1 million (Q2 2025) per Business Quant data.